Relationship between Pharmacokinetic/Pharmacodynamic Target Attainment and Microbiological Outcome in Critically Ill COVID-19 Patients with Documented Gram-Negative Superinfections Treated with TDM-Guided Continuous-Infusion Meropenem

Biomarkers Predicting Tissue Pharmacokinetics of Antimicrobials in Sepsis: A Review

(2022) Maria Sanz Codina et al.   CLINICAL PHARMACOKINETICS

Nosocomial infections associated to COVID-19 in the intensive care unit: clinical characteristics and outcome

(2021) Tommaso Bardi et al.   EUROPEAN JOURNAL OF CLINICAL MICROBIOLOGY & INFECTIOUS DISEASES

An evidence-based multidisciplinary approach focused at creating algorithms for targeted therapy of IVACs caused by Enterobacterales in critically ill adult patients

(2021) Milo Gatti et al.   Expert Review of Anti-Infective Therapy

Target Site Pharmacokinetics of Meropenem: Measurement in Human Explanted Lung Tissue by Bronchoalveolar Lavage, Microdialysis, and Homogenized Lung Tissue

(2021) Michael Paal et al.   ANTIMICROBIAL AGENTS AND CHEMOTHERAPY

A descriptive case series of pharmacokinetic/pharmacodynamic target attainment and microbiological outcome in critically ill patients with documented severe extensively drug-resistant Acinetobacter baumannii bloodstream infection and/or ventilator-associated pneumonia treated with cefiderocol

(2021) Milo Gatti et al.   Journal of Global Antimicrobial Resistance

Assessment of a PK/PD Target of Continuous Infusion Beta-Lactams Useful for Preventing Microbiological Failure and/or Resistance Development in Critically Ill Patients Affected by Documented Gram-Negative Infections

(2021) Milo Gatti et al.   Antibiotics-Basel

An Evidence-Based Multidisciplinary Approach Focused on Creating Algorithms for Targeted Therapy of Infection-Related Ventilator-Associated Complications (IVACs) Caused by Pseudomonas aeruginosa and Acinetobacter baumannii in Critically Ill Adult Patients

(2021) Milo Gatti et al.   Antibiotics-Basel

Antimicrobial therapeutic drug monitoring in critically ill adult patients: a Position Paper#

(2020) Mohd H. Abdul-Aziz et al.   INTENSIVE CARE MEDICINE

Clinical course and risk factors for mortality of adult inpatients with COVID-19 in Wuhan, China: a retrospective cohort study

(2020) Fei Zhou et al.   LANCET

Secondary Infections in Patients Hospitalized with COVID-19: Incidence and Predictive Factors

(2020) Marco Ripa et al.   CLINICAL MICROBIOLOGY AND INFECTION

Predictors of hospital-acquired bacterial and fungal superinfections in COVID-19: a prospective observational study

(2020) Marco Falcone et al.   JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY

Pharmacodynamic attainment of the synergism of meropenem and fosfomycin combination against Pseudomonas aeruginosa producing metallo-β-lactamase

(2019) James Albiero et al.   ANTIMICROBIAL AGENTS AND CHEMOTHERAPY

What Antibiotic Exposures Are Required to Suppress the Emergence of Resistance for Gram-Negative Bacteria? A Systematic Review

(2019) Chandra Datta Sumi et al.   CLINICAL PHARMACOKINETICS

Pneumonia and Renal Replacement Therapy Are Risk Factors for Ceftazidime-Avibactam Treatment Failures and Resistance among Patients with Carbapenem-Resistant Enterobacteriaceae Infections

(2018) Ryan K. Shields et al.   ANTIMICROBIAL AGENTS AND CHEMOTHERAPY

OUP accepted manuscript

(2018)   CLINICAL INFECTIOUS DISEASES

A Guide to Utilization of the Microbiology Laboratory for Diagnosis of Infectious Diseases: 2018 Update by the Infectious Diseases Society of America and the American Society for Microbiologya

(2018) J Michael Miller et al.   CLINICAL INFECTIOUS DISEASES

Treatment of Infections Caused by Extended-Spectrum-Beta-Lactamase-, AmpC-, and Carbapenemase-Producing Enterobacteriaceae

(2018) Jesús Rodríguez-Baño et al.   CLINICAL MICROBIOLOGY REVIEWS

Prolonged versus short-term intravenous infusion of antipseudomonal β-lactams for patients with sepsis: a systematic review and meta-analysis of randomised trials

(2018) Konstantinos Z Vardakas et al.   LANCET INFECTIOUS DISEASES

The combination of fosfomycin plus meropenem is synergistic for Pseudomonas aeruginosa PA01 in a Hollow Fiber Infection Model (HFIM).

(2018) G.L. Drusano et al.   ANTIMICROBIAL AGENTS AND CHEMOTHERAPY

Effect of Piperacillin-Tazobactam vs Meropenem on 30-Day Mortality for Patients With E coli or Klebsiella pneumoniae Bloodstream Infection and Ceftriaxone Resistance

(2018) Patrick N. A. Harris et al.   JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION

Continuous versus Intermittent β-Lactam Infusion in Severe Sepsis. A Meta-analysis of Individual Patient Data from Randomized Trials

(2016) Jason A. Roberts et al.   AMERICAN JOURNAL OF RESPIRATORY AND CRITICAL CARE MEDICINE

Emerging broad-spectrum resistance in Pseudomonas aeruginosa and Acinetobacter baumannii : Mechanisms and epidemiology

(2015) Anaïs Potron et al.   INTERNATIONAL JOURNAL OF ANTIMICROBIAL AGENTS

The effect of pathophysiology on pharmacokinetics in the critically ill patient — Concepts appraised by the example of antimicrobial agents

(2014) Stijn I. Blot et al.   ADVANCED DRUG DELIVERY REVIEWS

How do we use therapeutic drug monitoring to improve outcomes from severe infections in critically ill patients?

(2014) Gloria Wong et al.   BMC INFECTIOUS DISEASES

Stability of Generic Meropenem Solutions for Administration by Continuous Infusion at Normal and Elevated Temperatures

(2014) Loretta Franceschi et al.   THERAPEUTIC DRUG MONITORING

CharacterizingIn VivoPharmacodynamics of Carbapenems against Acinetobacter baumannii in a Murine Thigh Infection Model To Support Breakpoint Determinations

(2013) Shawn H. MacVane et al.   ANTIMICROBIAL AGENTS AND CHEMOTHERAPY

Multidrug-resistant, extensively drug-resistant and pandrug-resistant bacteria: an international expert proposal for interim standard definitions for acquired resistance

(2011) A.-P. Magiorakos et al.   CLINICAL MICROBIOLOGY AND INFECTION

Randomized trial of combination versus monotherapy for the empiric treatment of suspected ventilator-associated pneumonia*

(2009) Daren K. Heyland et al.   CRITICAL CARE MEDICINE